Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to follow all study requirements, including visits, treatments, and lab tests, and who have signed a consent form agreeing to take part
- People who have been diagnosed with lymphoma, leukemia, or myeloma that has come back or has not responded to previous treatment
- People whose cancer cells carry the specific targets that CAR-T cell therapy is designed to work against, confirmed by laboratory testing
- People aged 14 to 75 years (inclusive), any gender
- People whose general physical functioning is rated at a level showing they are able to carry out light activity (an ECOG performance score of 2 or below)
- People whose haemoglobin level is at least 70g/L (blood transfusions to reach this level are allowed)
- People whose liver, kidney, heart, and lung function meet specific minimum standards set by the trial (confirm exact values with the trial site)
- People with a T-cell type tumour who meet specific requirements about how the tumour cells appear in the blood, based on laboratory testing (confirm details with trial site)
- People with plans to become pregnant who agree to use contraception during the study and for six months after, and who agree to immediately inform the research team if pregnancy occurs or is suspected
- People, or their legal guardian, who understand and have signed the informed consent form
- People whose life expectancy is longer than three months
Who may not be able to join:
- People with severe heart failure
- People with a history of severe lung disease
- People who also have another advanced cancer diagnosis
- People with a severe or ongoing infection that cannot be brought under control
- People with a serious autoimmune disease or a condition where the immune system does not work properly from birth
- People with active hepatitis B or hepatitis C, confirmed by blood testing
- People with HIV infection or syphilis
- People with a history of severe allergic reactions to biological products, including antibiotics
- People who have had a stem cell transplant from a donor within the last six months
- People who have previously received CAR-T therapy or any other gene-modified cell therapy
- People where the trial doctor believes participation could increase health risks or affect the reliability of the study results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Weiwei w Tian, MD, Shanxi Bethune Hospital
Phone: 008613485304136
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety: Incidence and severity of adverse events; Efficacy: Remission Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.